Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Lung Cancer treatment details. Biologic therapy. Massachusetts General Hospital, Boston, MA, United States

Survival: 20.3 months
Toxicity Grade: 5
Treatments: Biologic therapy
Country: United States
City/State/Province: Boston, MA
Hospital: Massachusetts General Hospital
Journal: Link
Date: 6/2013

This phase 3 study involved ALK-positive lung cancer patients who had received prior platinum-based chemotherapy. Patients were divided into two separate treatment groups. Group A consisted of 173 patients with a median age of 51 years and 43% male. Group B had 174 patients with a median age of 49 years and 45% male.

Patients in group A were treated with the biologic therapy agent crizotinib, a tyrosine kinase inhibitor that interferes with cancer cell growth.

Patients in group B received chemotherapy with either pemetrexed or docetaxel.

Treatment-related deaths due to cardiac toxicity and pneumonia were reported for group A. Grade 3-4 shortness of breath, fatigue, and constipation were also reported.

There was one treatment-related death due to sepsis (infection) in group B. Grade 3-4 fatigue and shortness of breath were also reported.

The median progression-free survival for groups A and B was 7.7 and 3.0 months, respectively.
The median overall survival for groups A and B was 20.3 and 22.8 months, respectively.

This study was supported by Pfizer.

Correspondence: Dr. Alice T. Shaw; email:

E-mail to a Friend Email Physician More Information